NDA 021438 · Ani Pharms
Innopran Xl
Propranolol Hydrochloride · Oral
Last checked: Nov 20, 2026Latest source record: Dec 22, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2003
Mar 12, 2003
Approved uses
1
Original approval plus efficacy supplements
Registered trials
392
63 Phase 3, 46 recruiting
FAERS reports
11,452
7,760 serious, 1,483 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 27, 2026.
INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood...
Mechanism: The mechanism of the antihypertensive effect of propranolol has not been established. Among factors that contribute to the antihypertensive action are: (1) decreased cardiac output, (2) inhibition of renin release by the kidneys, and (3) diminution of tonic sympathetic nerve outflow from vasomotor centers in the brain. Although total peripheral resistance may increase initially, it readjusts to or below the pretreatment level with chronic use. Effects of propranolol on plasma volume appear to be minor and somewhat variable.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- INNOPRAN XL · PROPRANOLOL HYDROCHLORIDE 80MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE BX
- INNOPRAN XL · PROPRANOLOL HYDROCHLORIDE 120MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE BX
Clinical trials
Interventional ClinicalTrials.gov studies with "Propranolol" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison StudyPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06972056 · 1,335 participants (planned) · Start Jul 9, 2025 · Primary completion Mar 1, 2029
Drug: Atogepant 60 mg; Propranolol 160 mg and 1 more · For: Migraine
Sites: Hazel Green, Alabama; Flagstaff, Arizona; Phoenix, Arizona · 39 sites in all
- Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and RehabilitationPivotal-lookingTerminated
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00675714 · 1,126 participants · Start Jan 2004 · Primary completion Sep 2018
Drug: Humatrope; Ketoconazole and 5 more · For: Burns
Sites: Galveston, Texas
Center for Vascular Pathology, MoscowAcademic, hospital or other
NCT05106179 · 1,000 participants (planned) · Start Dec 2021 · Primary completion Dec 2022
Drug: Atenolol Pill; Propranolol Pill · For: Spinal Tumor; Spinal Hemangioma; Beta Blocker Toxicity
Sites: Moscow, Russia
- A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of MigrainePivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00236561 · 786 participants · Start Apr 2001
Drug: topiramate, propranolol · For: Migraine; Common Migraine; Classic Migraine and 1 more
- Beta Blocker Use In Traumatic Brain Injury Based On The High-Sensitive Troponin T StatusPivotal-lookingStatus unknown
Hamad Medical CorporationIndustry
NCT04508244 · 771 participants (planned) · Start Dec 29, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Propranolol · For: Trauma; Brain Injuries; Stress Reaction and 2 more
Sites: Doha, Qatar
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,808
- drug ineffective1,270
- nausea925
- product use in unapproved indication877
- product use issue870
- headache801
- fatigue776
- toxicity to various agents694
- diarrhoea630
- drug intolerance598
- dyspnoea568
- dizziness555
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 101 |
| 2005 | 169 |
| 2006 | 128 |
| 2007 | 100 |
| 2008 | 82 |
| 2009 | 154 |
| 2010 | 178 |
| 2011 | 172 |
| 2012 | 212 |
| 2013 | 145 |
| 2014 | 146 |
| 2015 | 153 |
| 2016 | 232 |
| 2017 | 250 |
| 2018 | 375 |
| 2019 | 401 |
| 2020 | 579 |
| 2021 | 875 |
| 2022 | 1,304 |
| 2023 | 1,480 |
| 2024 | 1,877 |
| 2025 | 1,270 |
| 2026 | 1,069 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Innopran XL (Propranolol HCl)
2024 spending
$2.7M
Beneficiaries
170
584 claims
Per beneficiary
$16,004
$70.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,035,573 |
| 2021 | $3,171,762 |
| 2022 | $3,124,222 |
| 2023 | $3,126,929 |
| 2024 | $2,720,762 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis.
Steenen SA, van Wijk AJ, van der Heijden GJ, et al. · J Psychopharmacol 2016 · Comparative Study, Meta-Analysis
- A randomized, controlled trial of oral propranolol in infantile hemangioma.
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, et al. · N Engl J Med 2015 · Clinical Trial, Phase II, Clinical Trial, Phase III
- Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder.
Beversdorf DQ, Ferguson B, Hunter S, et al. · Psychopharmacology (Berl) 2024 · Randomized Controlled Trial, Multicenter Study
- Oral propranolol in prevention of severe retinopathy of prematurity: a systematic review and meta-analysis.
Stritzke A, Kabra N, Kaur S, et al. · J Perinatol 2019 · Meta-Analysis, Systematic Review
- Propranolol Normalizes Metabolomic Signatures Thereby Improving Outcomes After Burn.
Rehou S, de Brito Monteiro L, Auger C, et al. · Ann Surg 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
· JAMA 1982 · Clinical Trial, Randomized Controlled Trial
Sponsor: Ani Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.